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ABSTRACT
Objective: To estimate isotretinoin exposure in Dutch
pregnant women despite the implemented pregnancy
prevention programme (PPP) and second, to analyse
the occurrence of adverse fetal or neonatal outcomes
in these isotretinoin exposed pregnancies.
Design: Population-based study.
Setting: The Netherlands.
Participants: A cohort of 203 962 pregnancies with
onset between 1 January 1999 and 1 September 2007
consisting of 208 161 fetuses or neonates.
Main outcome measures: Isotretinoin exposure in
the 30 days before or during pregnancy. Proportions of
adverse fetal or neonatal outcomes, defined as
intrauterine deaths ≥16 week of gestation and neonates
with major congenital anomalies. ORs with 95% CIs
adjusted for maternal age were calculated to estimate
the risk of adverse fetal or neonatal outcome after
maternal isotretinoin exposure.
Results: 51 pregnancies, 2.5 (95% CI 1.9 to 3.3) per
10 000 pregnancies, were exposed to isotretinoin despite
the pregnancy prevention programme. Forty-five of these
pregnancies, 2.2 (95% CI 1.6 to 2.9) per 10 000
pregnancies, were exposed to isotretinoin during
pregnancy and six additional women became pregnant
within 30 days after isotretinoin discontinuation. In 60% of
isotretinoin exposed pregnancies, women started
isotretinoin while already pregnant. In five out of the 51
isotretinoin exposed pregnancies (53 fetuses), 9.4% (95%
CI 1.3% to 17.6%), had an adverse fetal or neonatal
outcome. The OR for adverse fetal or neonatal outcomes
after isotretinoin exposure in 30 days before or during
pregnancy was 2.3 (95% CI 0.9 to 5.7) after adjustment
for maternal age.
Conclusions: Although a PPP was already implemented
in 1988, we showed that isotretinoin exposed pregnancies
and adverse fetal and neonatal events potentially related to
the exposure still occur. These findings from the
Netherlands add to the evidence that there is no full
compliance to the isotretinoin PPP in many Western
countries. Given the limited success of iPLEDGE, the
question is which further measures are able to improve
compliance.
INTRODUCTION
Isotretinoin, a vitamin A derivative, is
licensed in the European Union (EU) since
1983 and is indicated for systemic treatment
of severe acne (such as nodular or conglo-
bate acne or acne at risk of permanent scar-
ring) in patients resistant to adequate
courses of standard therapy with systemic
antibacterials and topical therapy.1 The
teratogenic potential is an important charac-
teristic of isotretinoin. Animal studies already
suggested teratogenic effects in humans and
isotretinoin has been contraindicated for use
during pregnancy since the very beginning
of the marketing authorisation. Despite this
contraindication, the first cases of congenital
anomalies after isotretinoin use during preg-
nancy were documented already in 1983.2 As
described by Lammer et al3 in 1985, isotreti-
noin embryopathy consists of craniofacial,
cardiac, thymic and central nervous system
defects. They found a relative risk of 26 for
Strengths and limitations of this study
▪ This is the first population-based study in the
European Union (EU) on isotretinoin exposure
during pregnancy in a large cohort of more than
200 000 pregnancies which enabled estimating
isotretinoin exposure rates among pregnant
women and its consequences on a nationwide
scale.
▪ From the virtually complete and detailed drug-
dispensing data, isotretinoin exposure could only
be estimated since drug-dispensing data does
not ascertain actual drug use and precise expos-
ure intervals. However, patients coming for refills
are usually taking their drug.
▪ Spontaneous abortions before gestational age of
16 weeks and elective abortions were not
included in our cohort and therefore our results
probably underestimate the number of
isotretinoin-exposed pregnancies and its
consequences.
▪ Specific teratogenic risks could not be estimated
with data lacking information on pregnancies until
16 weeks of gestation and lacking detailed descrip-
tions of adverse fetal and neonatal outcomes.
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this group of major congenital malformations after sys-
temic isotretinoin exposure during some parts of the
first 10 weeks after conception.3 Elective termination of
pregnancy (ETOP) was decided in more than 50% of
exposed pregnancies and 20% of the remaining preg-
nancies ended in a first trimester spontaneous abortion.3
Reports of congenital anomalies after isotretinoin use
accumulated and consequently, in 1988 the marketing
authorisation holder of isotretinoin implemented a
world-wide Pregnancy Prevention Programme (PPP) to
better prevent pregnancies among systemic isotretinoin
users.4 The PPP included an educational programme for
prescribers and patients including material to be used in
counselling women about the need to prevent preg-
nancy while taking isotretinoin. Conditions for prescrib-
ing included a negative pregnancy test, the use of
reliable contraception and a signed patient consent
form.4 In 2003, a review of isotretinoin by the European
Medicine Agency (EMA) resulted in a compulsory
European harmonised PPP for all isotretinoin contain-
ing products.1 The elements of the European wide PPP
are listed in box 1.
The safe use of isotretinoin in women of reproductive
age is in the interest of public health because of the poten-
tial risk of spontaneous and elective abortions, and, more
importantly, children with major congenital anomalies
require continuous healthcare throughout their life.
Although a PPP has been implemented in the EU, preg-
nancies during isotretinoin therapy still occur.5 6 The regu-
latory authorities of 16 EU member states responded in
2009 to a survey that isotretinoin exposed pregnancies
have occurred in their country.7 A French study between
2003 and 2006 estimated a pregnancy rate from 0.4 to 1.2/
1000 female isotretinoin users within reproductive age.6
Studies in the Netherlands observed that only 52–59% of
the female isotretinoin users of reproductive age used con-
comitant hormonal contraceptives, which was higher than
the 39–46% observed in the general female population of
similar age, but lower than anticipated.8 9 Although these
studies show limited compliance with the isotretinoin PPP,
it is not known whether isotretinoin exposure also occurs
during pregnancy and what the outcome of these preg-
nancies is. Therefore, the objective of our study was to esti-
mate isotretinoin exposure in Dutch pregnant women
despite the implemented PPP and second, to analyse the
occurrence of adverse fetal and neonatal outcomes in
these isotretinoin exposed pregnancies.
METHODS
Data sources
For this population-based study a cohort of 203 962 preg-
nancies consisting of 208 161 fetuses was constructed
using a linkage between the PHARMO Database
Network and the Netherlands Perinatal Registry (PRN).
The PHARMO Database Network is a dynamic
population-based cohort including, among other infor-
mation, drug-dispensing records from community phar-
macies for more than 3 million individuals in the
Netherlands (approximately 20% of the Dutch popula-
tion) that are collected since 1986.10 The drug-
dispensing data contain the following information per
prescription: the Anatomical Therapeutic Chemical
(ATC) classification of the drug, dispensing date,
regimen, quantity dispensed and estimated length of
duration of use.11 The PRN is a nationwide registry that
contains linked and validated data from four databases:
the national obstetric database for midwives (LVR-1),
the national obstetric database for gynaecologists
(LVR-2), the national obstetric database for general
practitioners (LVR-h) and the national neonatal/paedi-
atric database (LNR).12 The registry contains informa-
tion about care before, during and after delivery as well
as maternal and neonatal characteristics and outcome of
95% of 180 000 pregnancies annually in the
Netherlands with a gestational age of at least 16 weeks.
The PRN includes information on pregnancy outcome
including congenital anomalies detected during preg-
nancy, at birth or within the first year after birth. The
probabilistic linking method between PHARMO and
PRN has been described in detail elsewhere but was gen-
erally based on the birth date of the mother and child
and their postal zip codes.13 To be included in the
cohort the mother should be registered in the commu-
nity pharmacy database of PHARMO during the whole
pregnancy. The date of conception was estimated based
on the last menstrual period or ultrasound, as recorded
in the PRN, and was truncated to full weeks.
Isotretinoin dispensings
All dispensings for systemic (oral) isotretinoin (ATC
D10BA01) filled in community pharmacies by women
Box 1 Elements of the European Union isotretinoin preg-
nancy prevention programme
1. Isotretinoin is contraindicated in pregnant women and should
only be initiated in women of reproductive age who understand
the teratogenic risk and the need for regular follow-up.
2. Use of effective contraceptive measures from 4 weeks before
isotretinoin initiation until 4 weeks after treatment discontinu-
ation. At least one and preferably two complementary forms of
contraception including a barrier method should be used.
3. Pregnancy testing should be performed before, during and
5 weeks after discontinuation of isotretinoin.
4. Isotretinoin should only be prescribed by or under the supervi-
sion of a physician with experience in the use of systemic
retinoids.
5. Prescription should be limited to 30 days of treatment and con-
tinuation of treatment requires a new prescription.
6. Dispensing of isotretinoin should occur within a maximum of
7 days after prescription.
7. Educational programmes for healthcare professionals including
prescribers and pharmacists, and patients are in place to
inform them about the teratogenic risk and to create awareness
of the pregnancy prevention programme.
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included in our cohort within the 12 months period
before or during pregnancy were extracted from the
PHARMO Database Network. Considering a daily
dosage of 0.5–1 mg/kg daily,1 isotretinoin prescriptions
dispensed on the same day were assumed to be used
simultaneously and therefore these dispensings were
pooled and considered as one dispensing (eg, the pre-
scriptions of a 10 and 20 mg tablets dispensed at the
same time to reach a daily dosage of 30 mg). For each
isotretinoin dispensing, the length of the dispensing was
calculated by dividing the total number of prescribed
units by the number of units (doses) to be taken per
day. In case isotretinoin dispensings that were pooled
together had different lengths, the length of the single
dispensing with the longest duration was used. To assess
compliance with the PPP, we calculated the proportion
of dispensings that exceeded 30 days, which is the
maximum length according to the EU PPP.
Drug exposure interval
For all pregnancies (N=203 962) with gestational age of
at least 16 weeks included in the cohort, isotretinoin
exposure was estimated based on isotretinoin dispensing
data (ATC D10BA01) filled by the mother during the
12 months period before and during pregnancy.
Exposure in person time (days) was calculated by divid-
ing the total number of prescribed units by the number
of prescribed units per day. Isotretinoin exposure periods
were defined considering a possible overlap of isotreti-
noin dispensings. Gaps, isotretinoin free periods between
two isotretinoin dispensings, were not permitted
meaning that an isotretinoin exposure period ends once
an isotretinoin free period was identified. Using the start
and end date of the isotretinoin exposure period, the
number of days exposed was estimated for the following
exposure intervals: 30 days before conception, first
90 days of gestation (first trimester), day 90–179 of gesta-
tion (second trimester) and day 180—delivery (third tri-
mester). In addition, the entire period 30 days before
pregnancy until delivery as well as the period from
30 days before till the end of the first trimester were ana-
lysed separately.
Adverse fetal or neonatal outcomes
For each fetus (N=208 161), we determined whether
adverse fetal or neonatal outcomes were reported.
Adverse fetal or neonatal outcomes were defined as all
intrauterine deaths ≥16 week of gestation and liveborn
infants with major congenital anomalies. If possible, con-
genital anomalies were categorised into nine subgroups:
abdominal wall and skin disorders; cardiovascular
defects; defects in the digestive system; defects in the
nervous system; musculoskeletal defects; respiratory
defects; urogenital defects; multiple, syndrome or
chromosomal anomalies; or other congenital malforma-
tions. As we were interested in adverse fetal outcomes
potentially induced by maternal drug exposure,
chromosomal anomalies were not considered as an
adverse outcome in the analyses.
Analysis
Potential exposure to isotretinoin in the 30 days before
or during pregnancy was calculated per 10 000 pregnan-
cies for the aforementioned exposure intervals including
their 95% CIs. The proportions of adverse fetal outcome
among isotretinoin exposed and unexposed fetuses or
neonates were calculated including their 95% CIs. We
used multiple logistic regression models to calculate ORs
and 95% CIs to estimate associations between adverse
fetal or neonatal outcome and maternal isotretinoin
exposure. We adjusted for maternal age at conception
(<20, 20–24, 25–29, 30–34, ≥35), and if possible also for
calendar time (year of conception) and gender of the
infant. Analyses for specific congenital anomalies were
performed when >3 cases were observed. The t test or
Fisher exact test was used to derive p values when com-
paring continuous or categorical variables between study
groups. Statistical significance was assumed for two-sided
p values <0.05. Statistical analyses were performed using
SAS V.9.2 (SAS Institute, Cary, North Carolina, USA).
RESULTS
Between 1 January 1999 and 1 September 2007 in the
Netherlands, a total of 203 962 pregnancies correspond-
ing to 208 161 fetuses (including multiple births) were
included in our study. The mean maternal age at con-
ception was 30.3 years (SD 4.6) and mean duration of
pregnancy was 39 weeks and 3 days (SD 19 days).
Isotretinoin dispensings
A total of 416 isotretinoin dispensings to 130 of the
203 962 women in the 12 months period before or
during pregnancy were identified. In 139 of the 416 iso-
tretinoin dispensings (33.4%), the dispensing consisted
of >30 days of isotretinoin use. Figure 1 shows that the
Figure 1 Percentage of isotretinoin dispensings exceeding
the maximum duration of 30 days by calendar year.
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percentage of isotretinoin dispensings in the year before
or during pregnancy exceeding the maximum duration
of 30 days decreased over calendar time from 50% in
2001 to 13% in 2007.
Isotretinoin exposed pregnancies
Demographics for isotretinoin exposed and unexposed
pregnancies are presented in table 1.
Overall, 51 pregnancies, 2.5 (95% CI 1.9 to 3.3) per
10 000 pregnancies, were potentially exposed to isotreti-
noin in the 30 days before conception or during preg-
nancy, despite the implemented PPP. Forty-five pregnant
women, 2.2 (95% CI 1.6 to 2.9) per 10 000 pregnancies,
were estimated to be exposed to isotretinoin during preg-
nancy of whom 27 (60%) started isotretinoin treatment
while already being pregnant. In 18 pregnancies (40%),
the conception occurred during isotretinoin treatment.
Six pregnancies were identified within 1 month after iso-
tretinoin discontinuation and were estimated to be
exposed only before conception. In 40 out of 203 962
pregnancies, 2.0 (95% CI 1.4 to 2.6) per 10 000 pregnan-
cies, an isotretinoin prescription was filled during preg-
nancy and 32 pregnancies, 1.6 (95% CI 1.1 to 2.2) per
10 000 pregnancies, received isotretinoin more than
once during pregnancy. The number of isotretinoin dis-
pensings per pregnancy ranged from 1 to 7, with a
median of 2.5. The estimated isotretinoin exposure per
exposure interval is presented in table 2.
Among the pregnancies estimated to be exposed to
isotretinoin during pregnancy (N=45), the number of
exposed days during pregnancy ranged from 3 to
236 days with a median of 63 days. Figure 2 shows that
Table 1 Description of the study population
Isotretinoin exposed* Isotretinoin unexposed P Value
Pregnancies (N=203 962) 51 203 911
Mean (±SD) maternal age at conception in years (95% CI) 29.1 (4.9) (27.8 to 30.5) 30.3 (4.7) (30.3 to 30.3) 0.56
Mean (±SD) gestational age at delivery in weeks (95% CI) 39 (25 days) (38 to 40) 39, 3 days (19 days)
(39, 3 days–39, 3 days)
0.33
Fetuses (N=208 161) 53 208 108
Gender (boy %) 47.2% (33.3–61.1) 51.5% (51.3–51.7) 0.53
Maternal age at conception in years, N, column % 0.37
<20 2 (3.8%) 4063 (2.0%)
≥20–25 7 (13.2%) 22 144 (10.6%)
≥25–30 21 (39.6%) 68 366 (32.9%)
≥30–35 14 (26.4%) 81 581 (39.2%)
≥35 9 (17.0%) 31 951 (15.4%)
Gestational age at delivery in weeks, N, column % 0.64
<27 1 (1.9%) 2198 (1.1%)
27–30 1 (1.9%) 1167 (0.6%)
31–33 0 (0.0%) 2008 (1.0%)
34–36 3 (5.7%) 7126 (3.4%)
37–39 12 (22.6%) 50 854 (24.4%)
>39 36 (67.9%) 144 755 (69.5%)
Adverse fetal outcome, N; % (95% CI) 5;
9.4% (1.3 to 17.6)
9041;
4.3% (4.3 to 4.4)
0.08
*In the 30 days before conception or during pregnancy.
Table 2 Potential isotretinoin exposed pregnancies per exposure interval
Isotretinoin exposure interval*
Exposed
pregnancies
(N=203 962)
Exposed pregnancies per
10 000 pregnancies
(95% CI)
Median number of
days exposed
per pregnancy (range)
30 days before conception (30 days
period)
23 1.1 (0.7 to 1.7) 24 (3–30)
1st trimester (90 days period) 28 1.4 (0.9 to 2.0) 31 (3–88)
2nd trimester (90 days period) 25 1.2 (0.8 to 1.8) 57 (1–90)
3rd trimester (90–103 days period) 26 1.3 (0.9 to 1.8) 62 (1–103)
During pregnancy (270 days period) 45 2.2 (1.6 to 2.9) 63 (3–236)
30 days before or during pregnancy
(300 days period)
51 2.5 (1.9 to 3.3) 63 (7–236)
30 days before or during 1st trimester
(120 days period)
35 1.7 (1.2 to 2.4) 32 (7–114)
*Categories are not mutually exclusive but indicate the number of pregnancies exposed to isotretinoin during that exposure interval.
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the number of women estimated to be exposed to isotre-
tinoin during pregnancy was the highest in 2006 with
3.5 pregnancies (95% CI 1.7 to 6.4) per 10 000
pregnancies.
Adverse fetal or neonatal outcomes
Independent of isotretinoin exposure, adverse fetal or
neonatal outcomes were observed for 9046 of the
208 161 fetuses (4.4% (95% CI 4.3% to 4.4%)). The 51
pregnancies potentially exposed to isotretinoin in
30 days before conception or during pregnancy corre-
sponded to 53 fetuses or neonates including two mul-
tiple births. Five of these, all singletons, had an adverse
fetal or neonatal outcome (9.4% (95% CI 3.5% to
19.7%)). These included three intrauterine deaths and
two liveborn infants with major congenital anomalies
(see table 3). Among those potentially exposed during
pregnancy only (N=47), 6.4% (95% CI 1.7% to 16.4%)
had an adverse fetal or neonatal outcome. The OR for
adverse fetal or neonatal outcome after potential isotre-
tinoin exposure in the 30 days before or during
pregnancy was 2.3 (95% CI 0.9 to 5.7) after adjustment
for maternal age (see table 3). Restricting the analysis to
the potential isotretinoin exposure during pregnancy,
the adjusted OR of an adverse fetal outcome was 1.5
(95% CI 0.5 to 4.8). The number of cases was too low to
allow for adjustments in addition to maternal age. The
adjusted OR of any fetal or neonatal outcome was sig-
nificantly increased at 3.6 (95% CI 1.4 to 9.4) for isotre-
tinoin exposure during the 30 days before or first
trimester of pregnancy.
DISCUSSION
This study shows that 2 per 10 000 pregnancies were
exposed to isotretinoin despite the PPP which is imple-
mented to prevent isotretinoin use during pregnancy.
Although this study was not intended to estimate the
teratogenic risks of isotretinoin, adverse fetal and neo-
natal outcomes potentially related to isotretinoin expos-
ure were observed. That there are still women who are
using isotretinoin during pregnancy despite the imple-
mentation of the PPP is of major concern. Especially
since the majority of isotretinoin exposed women (60%)
were already pregnant at the time of first isotretinoin pre-
scription and it seems that pregnancy was not always
excluded before isotretinoin dispensing (box 1). These
exposed pregnancies could probably have been pre-
vented when appropriate pregnancy testing would have
been performed. Furthermore, it was earlier demon-
strated that women of reproductive age treated with iso-
tretinoin did not always use effective contraceptive
measures because only up to 59% of these women con-
comitantly used hormonal contraceptives.8 9 Limited
compliance with the PPP was also observed in a survey
among Dutch pharmacists which indicated that in 2007
and 2011, 44% and 49% of pharmacists, respectively,
checked the use of contraception at every isotretinoin dis-
pensing.14 The percentage of pharmacists that asked for
negative pregnancy tests was stable with 15% and 16%,
respectively, and is in line with our study which demon-
strated that pregnancy is not always excluded before initi-
ating isotretinoin and result in isotretinoin exposed
Table 3 ORs for adverse fetal and neonatal outcomes and isotretinoin exposure in 30 days before or during pregnancy
Isotretinoin exposed fetuses
Exposed fetuses
with adverse outcomes OR (95% CI) Adjusted OR* (95% CI)
During pregnancy (N=47) 3† 1.5 (0.5 to 4.8) 1.5 (0.5 to 4.8)
30 days before or during pregnancy (N=53) 5†‡ 2.3 (0.9 to 5.8) 2.3 (0.9 to 5.7)
30 days before or 1st trimester (N=35) 5†‡ 3.7 (1.4 to 9.5) 3.6 (1.4 to 9.4)
*Maternal age in categories (<20, 20–24, 25–29, 30–34, ≥35).
†Includes three intrauterine deaths.
1. In week 19, potentially exposed first 29 days following conception.
2. In week 35, potentially exposed 10 weeks following conception and from week 18 until week 32.
3. In week 38, also reported an unspecified septal defect; potentially exposed first 8 days following conception, during week 12 until week 24
and during week 28 until week 38.
‡Includes two liveborn infants with major congenital anomalies.
1. Neural tube defect, potentially exposed all 30 days before conception, not after conception.
2. Major congenital anomaly not further specified, potentially exposed the first 15 days of the 30 days before conception, not after conception.
Figure 2 Isotretinoin exposed pregnancies per 10 000
pregnancies by calendar year.
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pregnancies that could have been prevented. Our study
showed that compliance with the recommended
maximum length of prescription of 30 days was limited
since one-third of isotretinoin dispensings exceeded
30 days which however decreased from 50% in 1999 to
13% in 2007. Based on these results it is clear that compli-
ance with the PPP in the Netherlands between 1999 and
2007 was incomplete. These findings suggest an ongoing
need to educate healthcare professionals and patients on
the fetal risks of isotretinoin and the PPP, especially since
isotretinoin is mostly used in young women of reproduct-
ive age.
Previous studies on isotretinoin use during pregnancy
in other Western countries showed comparable results
indicating that limited compliance to the PPP is not
restricted to the Netherlands.6 15–17 In the USA, the
most recent isotretinoin PPP, called iPLEDGE, has been
implemented since 2006 and is stricter than the EU PPP.
iPLEDGE is an internet-based system that requires regis-
tration of all stakeholders with monthly updates on pre-
scription, pregnancy tests, contraceptive use and
acknowledgement of risks.17 The pregnancy rate among
isotretinoin users in the USA with the iPLEDGE PPP was
estimated at 2.7/1000 treatment courses and did not
change compared to the previous PPP called SMART
(System to Manage Accutane-Related Teratogenicity)
while only small improvements in compliance with
contraceptive measures were observed.17 18 Apparently,
also iPLEDGE does not bring complete security because
further restrictive measures as in iPLEDGE do not seem
to improve the results and may add unnecessary burden
to the healthcare system since healthcare professionals
and patients need to register and verify information on
a monthly basis.4
Strengths and weaknesses of the study
A strength of this study is that we used a population-based
design including virtually complete and detailed drug-
dispensing data and pregnancy outcome data of a large
cohort, which enabled estimating nationwide isotretinoin
exposure rates among pregnant women. A known limita-
tion of using drug-dispensing data is that it does not
confirm the actual use of the drug under study and does
not provide information on the precise time window of
drug use. In addition, it is likely that women may change
or stop their medication use when they become aware of
pregnancy. However, it should be noted that our data
show that the majority (80%) of pregnant women who
filled prescriptions for isotretinoin came back for refills,
suggesting that they really used the drug.
This study provides no information on spontaneous abor-
tions that occurred until gestational age of 16 weeks and
ETOPs because these data are not captured in the PRN data-
base and these pregnancies were thus not included in our
cohort. This resulted in an underestimation of the number
of pregnancies that were potentially exposed to isotretinoin
in the 30 days before or during pregnancy and the adverse
fetal and neonatal outcomes. Studies that estimated the
teratogenic risk of isotretinoin using prospectively documen-
ted isotretinoin exposed pregnancies found much higher
proportions of pregnancies resulting in spontaneous abor-
tion, stillbirth or reported congenital malformations, that is,
36% (13 of the 36 fetuses)3 and 26% (6 of the 23 fetuses).5
Without detailed information on drug exposure prefer-
ably verified by the patient whether the drug was actually
taken and detailed descriptions of the diagnosed fetal
outcome as well as on spontaneous abortions, the terato-
genic risk of isotretinoin could not be accurately estimated.
With regard to the adverse fetal outcomes observed in our
study, we cannot exclude that they had any other aetiology
than isotretinoin exposure. Owing to the low number of
cases it was also not possible to adjust in the statistical ana-
lysis for important confounding factors other than mater-
nal age such as smoking, alcohol intake, previous
pregnancy outcomes and exposure to other potentially
teratogenic drugs. Detection bias may also have influenced
the incidence and estimated risks of congenital anomalies
since more detailed diagnostics might have been used in
pregnancies exposed to isotretinoin compared to the
unexposed pregnancies. Nevertheless, the results of our
study are in line with the undisputed embryotoxicity of iso-
tretinoin and suggestive of an increased risks of adverse
fetal or neonatal events when isotretinoin is dispensed for
use in the 30 days period before or during pregnancy.
Implications and future research
In the Netherlands, approximately 180 000 pregnancies
are reported annually.19 When extrapolating the 2.2
(95% CI 1.6 to 2.9) per 10 000 women potentially
exposed to isotretinoin during pregnancy to a national
level, there would be 29–52 isotretinoin-exposed preg-
nancies per year yielding unnecessary risks for congeni-
tal anomalies and fetal deaths. Therefore, it is in the
interest of public health to implement effective PPPs
and improve these measures or their compliance as
much as possible to reduce isotretinoin use during preg-
nancy to the lowest possible level.
With the present study only the period 1999–2007 has
been evaluated. The past years in the Netherlands, the
PPP is communicated to healthcare professionals via
product information,20 national general practitioner
standards on treatment of acne,21 drug prescription and
dispensing systems,22 the website of the Dutch Medicines
Evaluation Board23 and the common (national) litera-
ture on drug information.24 Furthermore, research on
isotretinoin use in the Netherlands and the PPP is con-
ducted and published in (inter)national scientific
medical journals.7–9 14 25–28 Consequently, data after
2007 are needed to judge if attention for the isotretinoin
PPP during recent years has improved the carefulness
with which isotretinoin is prescribed and dispensed.
Conclusions
Although a PPP was implemented almost 15 years ago,
we showed that there are still pregnancies exposed to
isotretinoin in the Netherlands which could have been
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prevented if appropriate exclusion of pregnancy before
isotretinoin initiation would have been performed.
These findings from the Netherlands add to the evi-
dence that there is no full compliance to the isotretinoin
PPP in many Western countries. Given the limited
success of iPLEDGE, the question is which further mea-
sures are able to improve compliance.
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